HIV-1 drug-resistance and drug-dependence

Retrovirology

Volumn 4, Issue , 2007, Pages

  Baldwin, Chris ^a   Berkhout, Ben ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BEVIRIMAT; CYCLOSPORIN A; ENFUVIRTIDE; ENVELOPE PROTEIN; GAG PROTEIN; PROTEINASE; T 1249; VICRIVIROC; VIRUS PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT; VIRUS ENVELOPE PROTEIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; REVIEW; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; ADDICTION; DRUG EFFECT; DRUG RESISTANCE; GENETIC VARIABILITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOPHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DRUG RESISTANCE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS; PHENOTYPE; SUBSTANCE-RELATED DISORDERS; VARIATION (GENETICS); VIRAL ENVELOPE PROTEINS;

EID: 37249075456     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-4-78     Document Type: Review

References (38)

1. Baldwin CE Sanders RW Deng Y Jurriaans S Lange JM Lu M Berkhout B: Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol 2004, 78:12428-12437. 525057 15507629 10.1128/JVI.78.22.12428-12437.2004
2. Menzo S Monachetti A Balotta C Corvasce S Rusconi S Paolucci S Baldanti F Bagnarelli P Clementi M. Processivity and drug-dependence of HIV-1 protease: Determinants of viral fitness in variants resistant to protease inhibitors. AIDS 2003, 17:663-671. 10.1097/ 00002030-200303280-00003 12646788
3. Weissenhorn W Dessen A Harrison SC Skehel JJ Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430. 10.1038/ 387426a0 9163431
4. Tan K Liu J Wang J Shen S Lu M: Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997, 94:12303-12308. 24915 9356444 10.1073/pnas.94.23.12303
5. Chan DC Fass D Berger JM Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273. 10.1016/ S0092-8674(00)80205-6 9108481
6. Lu M Blacklow SC Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995, 2:1075-1082. 10.1038/ nsb1295-1075 8846219
7. Wild CT Shugars DC Greenwell TK McDanal CB Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994, 91:9770-9774. 44898 7937889 10.1073/pnas.91.21.9770
8. Chen SS: Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol 1994, 68:2002-2010. 236667 7509005
9. Baldwin CE Sanders RW Berkhout B: Inhibiting HIV-1 entry with fusion inhibitors. Curr Med Chem 2003, 10:1633-1642. 10.2174/0929867033457124 12871113
10. Greenberg ML Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004, 54:333-340. 10.1093/jac/dkh330 15231762
11. Lu J Sista P Giguel F Greenberg M Kuritzkes DR: Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004, 78:4628-4637. 387671 15078945 10.1128/ JVI.78.9.4628-4637.2004
12. Baldwin CE Berkhout B: Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein. Retrovirology 2006, 3:84.
13. Perez-Alvarez L Carmona R Ocampo A Asorey A Miralles C Perez C Pinilla M Contreras G Taboada JA Najera R: Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1. J Med Virol 2006, 78:141-147. 10.1002/jmv.20520 16372284
14. Xu L Pozniak A Wildfire A Stanfield-Oakley SA Mosier SM Ratcliffe D Workman J Joall A Myers R Smit E Cane PA Greenberg ML Pillay D: Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother 2005, 49:1113-1119. 549241 15728911 10.1128/ AAC.49.3.1113-1119.2005
15. Poveda E Rodes B Toro C Martin-Carbonero L Gonzalez-Lahoz J Soriano V: Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 2002, 16:1959-1961. 10.1097/ 00002030-200209270-00014 12351957
16. Zollner B Feucht HH Schroter M Schafer P Plettenberg A Stoehr A Laufs R: Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 2001, 15:935-936. 10.1097/ 00002030-200105040-00015 11399967
17. Ray N Harrison JE Blackburn LA Martin JN Deeks SG Doms RW: Clinical resistance to enfuvirtide does not affect susceptibility to other classes of entry inhibitors. J Virol 2007, [Epub ahead of print]:.
18. Labrosse B Morand-Joubert L Goubard A Rochas S Labernardiere JL Pacanowski J Meynard JL Hance AJ Clavel F Mammano F: Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 2006, 80:8807-8819. 1563884 16912327 10.1128/JVI.02706-05
19. Sista PR Melby T Davison D Jin L Mosier S Mink M Nelson EL DeMasi R Cammack N Salgo MP Matthews TJ Greenberg ML Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates AIDS 2004 18 1787 1794 10.1097/ 00002030-200409030-00007 15316339
20. Wei X Decker JM Liu H Zhang Z Arani RB Kilby JM Saag MS Wu X Shaw GM Kappes JC: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46:1896-1905. 127242 12019106 10.1128/ AAC.46.6.1896-1905.2002
21. Tolstrup M Selzer-Plon J Laursen AL Bertelsen L Gerstoft J Duch M Pedersen FS: Ostergaard L Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS 2007, 21:519-521. 10.1097/QAD.0b013e3280187558 17301572
22. Hildinger M Dittmar MT Schult-Dietrich P Fehse B Schnierle BS Thaler S Stiegler G Welker R von Laer D: Membrane-anchored peptide inhibits human immunodeficiency virus entry J Virol 2001, 75:3038-3042. 115933 11222732 10.1128/JVI.75.6.3038-3042.2001
23. Lohrengel S Hermann F Hagmann I Oberwinkler H Scrivano L Hoffmann C von Laer D Dittmar MT: Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 2005, 79:10237-10246. 1182644 16051817 10.1128/JVI.79.16.10237-10246.2005
24. Nameki D Kodama E Ikeuchi M Mabuchi N Otaka A Tamamura H Ohno M Fujii N Matsuoka M: Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol 2005, 79:764-770. 538534 15613304 10.1128/ JVI.79.2.764-770.2005
25. Rimsky LT Shugars DC Matthews TJ: Determinants of human immunodeficiency virus type 1 resistance to gp41- derived inhibitory peptides. J Virol 1998, 72:986-993. 124569 9444991
26. Cole AL Yang OO Warren AD Waring AJ Lehrer RI Cole AM: HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J Immunol 2006, 176:6900-6905. 16709850
27. Gallo SA Wang W Rawat SS Jung G Waring AJ Cole AM Lu H Yan X Daly NL Craik DJ Jiang S Lehrer RI Blumenthal R: Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 2006, 281:18787-18792. 10.1074/jbc.M602422200 16648135
28. Pugach P Marozsan AJ Ketas TJ Landes EL Moore JP Kuhmann SE: HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virol 2007, 361:212-228. 10.1016/ j.virol.2006.11.004
29. Strizki JM Tremblay C Xu S Wojcik L Wagner N Gonsiorek W Hipkin RW Chou CC Pugliese-Sivo C Xiao Y Tagat JR Cox K Priestley T Sorota S Huang W Hirsch M Reyes GR Baroudy BM: Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005, 49:4911-4919. 1315929 16304152 10.1128/AAC.49.12.4911-4919.2005
30. Aberham C Weber S Phares W: Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins. J Virol 1996, 70:3536-3544. 190228 8648687
31. Braaten D Aberham C Franke EK Yin L Phares W Luban J: Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J Virol 1996, 70:5170-5176. 190472 8764025
32. Dorfman T Gottlinger HG: The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811. J Virol 1996, 70:5751- 5757. 190588 8709190
33. Franke EK Yuan HE Luban J: Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994, 372:359-362. 10.1038/372359a0 7969494
34. Thali M Bukovsky A Kondo E Rosenwirth B Walsh CT Sodroski J Gottlinger HG: Functional association of cyclophilin A with HIV-1 virions. Nature 1994, 372:363-365. 10.1038/372363a0 7969495
35. Towers GJ Hatziioannou T Cowan S Goff SP Luban J Bieniasz PD: Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003, 9:1138-1143. 10.1038/nm910 12897779
36. Yang R Aiken C: A mutation in alpha helix 3 of CA renders human immunodeficiency virus type 1 cyclosporin A-resistant and dependent: rescue by a second-site substitution in a distal region of CA. J Virol 2007, [Epub ahead of print]:.
37. Adamson CS Ablan SD Boeras I Goila-Gaur R Soheilian F Nagashima K Li F Salzwedel K Sakalian M Wild CT Freed EO: In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 2006, 80:10957-10971. 1642185 16956950 10.1128/ JVI.01369-06
38. Bezemer D Jurriaans S Prins M L. H Prins JM de Wolf F Berkhout B Coutinho R Back NK: Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS 2004, 18:1571-1577. 10.1097/ 01.aids.0000131357.52457.33 15238775